La cadena de opciones muestra datos clave de las opciones de acciones de Beyond Air a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Beyond Air..

Beyond Air (NASDAQ:XAIR) Bolsa, Cadena de Opciones

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Konskie,,Poland,-,May,27,,2024:,Korn,Ferry,Company,Logo

Pre-Market Outlook

BTDR

ESEA

XAIR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: KFY, XAIR, GMS, BTDR y ESEA.

5 acciones en el foco este miércoles: KFY, XAIR, GMS, BTDR y ESEA

Outlook
Based on our current outlook, for 2025 we expect Adjusted EBITDA, which excludes the non-cash impact of metal price lag, to be in the range of $620 million to $650 million and Free Cash Flow in excess of $120 million. For 2028, we expect Adjusted EBITDA, which excludes the non-cash impact of metal price lag, of $900 million and Free Cash Flow of $300 million.

News

Guidance

CSTM

Constellium Expects 2025 Adj EBITDA Of $620M-$650M, Free Cash Flow Over $120M And FY28 Adj EBITDA Of $900M, Free Cash Flow Of $300M

Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) raises FY2025 Adj EPS guidance from $4.50 to $4.55-$4.75 vs $4.40 analyst estimate..

Stanley Black & Decker Raises FY2025 Adj EPS Guidance from $4.50 to $4.55-$4.75 vs $4.40 Est

Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) raises FY2025 GAAP EPS guidance from $3.15-$3.45 to $3.35-$3.55 vs $3.50 analyst estimate..

Stanley Black & Decker Raises FY2025 GAAP EPS Guidance from $3.15-$3.45 to $3.35-$3.55 vs $3.50 Est

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) reported quarterly sales of $4.941 billion which beat the analyst consensus estimate of $4.285 billion by 15.32 percent. This is a 20.54 percent increase over sales of $4.099 billion the same period last year.

Earnings

Earnings Beats

SPOT

Spotify Technology Q2 Sales $4.941B Beat $4.285B Estimate

Armstrong World Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWI#NYSE">AWI</a>) raises FY2025 GAAP EPS guidance from $6.63-$6.77 to $6.93-$6.99 vs $6.93 analyst estimate..

Armstrong World Indus Raises FY2025 GAAP EPS Guidance from $6.63-$6.77 to $6.93-$6.99 vs $6.93 Est

Earnings Misses

Constellium Q2 EPS $0.25 Misses $0.28 Estimate, Sales $2.10B Beat $1.91B Estimate

United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) reported quarterly earnings of $1.55 per share which missed the analyst consensus estimate of $1.57 by 1.4 percent. This is a 13.41 percent decrease over earnings of $1.79 per share from the same period last year. The company reported quarterly sales of $21.20 billion which beat the analyst consensus estimate of $20.87 billion by 1.59 percent. This is a 2.83 percent decrease over sales of $21.82 billion the same period last year.

United Parcel Service Q2 Adj. EPS $1.55 Misses $1.57 Estimate, Sales $21.20B Beat $20.87B Estimate

Armstrong World Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWI#NYSE">AWI</a>) raises FY2025 Adj EPS guidance from $6.85-$7.15 to $7.15-$7.30 vs $7.02 analyst estimate. Raises FY2025 sales outlook from $1.570 billion-$1.610 billion to $1.600 billion-$1.630 billion vs $1.600 billion estimate.

Armstrong World Indus Raises FY2025 Adj EPS Guidance from $6.85-$7.15 to $7.15-$7.30 vs $7.02 Est; Raises FY2025 Sales Guidance from $1.570B-$1.610B to $1.600B-$1.630B vs $1.600B Est

Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.43 by 153.52 percent. This is a 0.92 percent decrease over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $3.945 billion which missed the analyst consensus estimate of $4.008 billion by 1.57 percent. This is a 1.96 percent decrease over sales of $4.024 billion the same period last year.

Stanley Black & Decker Q2 Adj. EPS $1.08 Beats $0.43 Estimate, Sales $3.945B Miss $4.008B Estimate

Armstrong World Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWI#NYSE">AWI</a>) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $1.78 by 17.35 percent. This is a 29.01 percent increase over earnings of $1.62 per share from the same period last year. The company reported quarterly sales of $424.600 million which beat the analyst consensus estimate of $404.153 million by 5.06 percent. This is a 16.30 percent increase over sales of $365.100 million the same period last year.

Armstrong World Indus Q2 Adj. EPS $2.09 Beats $1.78 Estimate, Sales $424.600M Beat $404.153M Estimate

In a bid to reduce dependency on vendors like Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), the Pentagon is experimenting with AI models from Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and OpenAI.
What Happened: The Pentagon and other federal agencies are evaluating AI models developed by Microsoft and OpenAI. These models are designed to extract data from analytics applications managed by contractors such as Palantir and Lockheed Martin, as reported <a href="https://www.investing.com/news/stock-market-news/dod-test-ai-models-that-make-it-easy-to-switch-from-vendors-like-palantir-4155825">by</a> investing.com on Monday.
The aim is to potentially free customers from vendor lock-in situations.
Major tech companies, including Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Microsoft, and Salesforce.com Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), are developing AI tools to simplify platform transitions for their customers. 
These tools can write code to transfer corporate data between applications or convert older programs into newer formats.
These AI capabilities could be used as leverage in contract negotiations with current providers like Palantir, as they could threaten to move agency data to competing analytics platforms such as Microsoft&#8217;s Power BI.
See Also: <a href="https://benzinga.com/markets/tech/25/07/46651922/samsung-inks-decade-long-16-5-billion-chip-manufacturing-pact-with-mystery-tech-giant-as-it-fights-t" target="_blank" rel="noopener">Elon Musk Confirms Tesla As the Mystery Big-Tech That Signed $16.5 Billion Chip Contract With Samsung: &#8216;I Will Walk The Line Personally&#8217; To Boost Progress</a>
Why It Matters: This development comes in the wake of a growing interest in AI technologies. Just earlier this month, tech analyst Dan Ives of Wedbush Securities raised his price target for Palantir, citing the company&#8217;s <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46339022/palantir-could-be-the-next-big-ai-winner-says-dan-ives-sees-12-pltr-stock-surge">AI strategy</a> as a key factor.
On the other hand, Microsoft has been under scrutiny for its <a href="https://www.benzinga.com/markets/tech/25/07/46507658/microsoft-ends-china-based-tech-support-for-pentagon-projects-amid-national-security-backlash">China-based tech support</a> for Pentagon projects. The company&#8217;s decision to discontinue this support could have influenced the DoD&#8217;s decision to explore alternative AI models.
Meanwhile, Palantir&#8217;s position in the AI landscape has also been a topic of debate, with co-founder Joe Lonsdale outlining a six-layer <a href="https://www.benzinga.com/markets/tech/25/07/46680292/peter-thiel-debates-6-layer-ai-future-with-palantir-cofounder-why-nvidia-is-untouchable-at-level-1-and-pltr-may-be-at-risk-in-level-4">AI investment framework</a> that raises concerns about the company&#8217;s competitive position.
Price Action: Palantir shares dipped 0.58% on Monday to close at $157.88, but gained 0.39% in premarket trading on Tuesday, according to <a href="http://pro.benzinga.com/">Benzinga Pro data</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/macro-economic-events/25/07/46653477/trump-mulls-little-rebate-for-americans-funded-by-tariff-revenue-but-heres-the-big-" target="_blank" rel="noopener">Trump Mulls &#8216;Little Rebate&#8217; For Americans Funded By Tariff Revenue — But Here&#8217;s The &#8216;Big Thing&#8217; He Wants To Do First</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

AMZN

MSFT

PLTR

Pentagon Tests AI Models By Microsoft, OpenAI To Ease Transition From Palantir, Lockheed Martin

Outlook components include:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">UnitedHealth Group 2025 Outlook ($ in millions, except per share data)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Operating Earnings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Optum</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$266,000 - $267,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$12,550 - $12,850</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">UnitedHealthcare</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$344,000 - $345,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9,000 - $9,300</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Eliminations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($164,500) - ($165,000)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total UnitedHealth Group</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$445,500 - $448,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$21,550 - $22,150</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Diluted</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Adjusted (a)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Earnings per Share</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">At least $14.65</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">At least $16.00</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">UnitedHealthcare 2025 Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">($ in millions; membership in thousands)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Employer &amp; Individual</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$79,600 - $80,100</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medicare &amp; Retirement</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$170,200 - $170,700</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Community &amp; State</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$94,200 - $94,700</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total UnitedHealthcare Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$344,000 - $345,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Earnings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9,000 - $9,300</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.6% - 2.7%</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

UnitedHealth Reestablishes FY2025 Guidance With Adjusted Earnings Of At Least $16.00 Per Share Versus Consensus Of $22.33, And Sales Guidance of $445.5B-$448B vs $449.503B Est

UnitedHealth Group Q2 2025 Adj. EPS $4.08 Misses $4.95 Estimate, Sales $111.616B Miss $111.694B Estimate

Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong said other G20 nations are now examining Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reserves following President Donald Trump&#8216;s establishment of a Strategic Bitcoin Reserve through executive order.
What Happened: &#8220;Now that the U.S. is doing this I think like the rest of the G20 countries and central banks are all starting to look at this. It just kind of instantly legitimized it,&#8221; Armstrong said Monday on the Shawn Ryan Show. The CEO noted that Trump&#8217;s move represents a dramatic shift from government skepticism just five years ago.
Trump signed an executive order in March creating the Strategic Bitcoin Reserve, funded <a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise">entirely through existing government</a> Bitcoin holdings obtained via criminal and civil asset forfeiture proceedings. White House AI and Crypto Czar David Sacks confirmed the reserve contains approximately 200,000 Bitcoin worth roughly $17 billion, requiring no taxpayer funding.
The reserve operates similarly to existing U.S. strategic stockpiles of gold, oil, palladium and rare minerals. Armstrong emphasized this historical context, calling it &#8220;a huge moment&#8221; that legitimizes Bitcoin as a strategic asset.
Trump has positioned himself as &#8220;the first crypto president,&#8221; declaring America must lead in financial technology to maintain global power. The executive order also established a U.S. Digital Asset Stockpile for other cryptocurrencies obtained through government proceedings.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46678490/bitcoin-drops-as-michael-saylors-strategy-halts-accumulation-streak-ethereum-dogecoin-also-dip-analyst-expects-violent-week-ahead">Bitcoin Drops As Michael Saylor&#8217;s Strategy Halts Accumulation Streak; Ethereum, Dogecoin Also Dip: Analyst Expects &#8216;Violent&#8217; Week Ahead</a>
Why It Matters: The G20 comprises 19 countries plus the European Union and the African Union, representing the world&#8217;s major economies, including China, Japan, Germany, and the UK. Armstrong&#8217;s comments suggest broader institutional adoption may follow US leadership.
Corporate Bitcoin adoption continues to expand. MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) leads with 607,770 Bitcoin, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) holds 11,509 Bitcoin according to Bitcoin Treasuries data. Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) ranks sixth with 18,430 Bitcoin.
Bitcoin traded around $118,895 as of Tuesday morning, up 0.03% as institutional accumulation patterns shift and markets await Federal Reserve <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46678490/bitcoin-drops-as-michael-saylors-strategy-halts-accumulation-streak-ethereum-dogecoin-also-dip-analyst-expects-violent-week-ahead">policy decisions this week</a>.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Brian Armstrong - Mining 21 Million Bitcoins, Satoshi Nakamoto and Elizabeth Warren &#x7C; SRS #222" width="500" height="281" src="https://www.youtube.com/embed/o5Tuj148mk4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46680503/us-stocks-settle-mixed-following-us-eu-trade-deal-investor-sentiment-edges-lower-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following US-EU Trade Deal: Investor Sentiment Edges Lower, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

MSTR

TSLA

Trump's Bitcoin Reserve Just 'Legitimized It'—Coinbase CEO Brian Armstrong Says G20 Nations Now Rushing To Build Their Own BTC Stockpiles

TD Cowen analyst Andrew Charles maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Buy and raises the price target from $19 to $21.

Price Target

Analyst Ratings

FWRG

TD Cowen Maintains Buy on First Watch Restaurant Gr, Raises Price Target to $21

Needham analyst Charles Shi maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and raises the price target from $22 to $28.

AMKR

Needham Maintains Buy on Amkor Tech, Raises Price Target to $28

U.S. stock futures rose on Tuesday after ending on a mixed note on Monday. Futures of major benchmark indices were higher.
Despite a mixed close, the S&amp;P 500 posted its sixth day of record closing high, and the Nasdaq also notched an all-time high on Monday.
The Federal Reserve Open Market Committee&#8217;s two-day meeting will begin today, ahead of its press conference, which will be held on Wednesday afternoon.
Investors await results from Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) today.
Meanwhile, the 10-year Treasury bond yielded 4.41% and the two-year bond was at 3.92%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 96.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.15%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.24%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.41%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.31%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Friday. The SPY was up 0.23% at $638.40, while the QQQ advanced 0.42% to $570.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Monday, the energy and information technology sectors on the S&amp;P 500 closed higher, bucking the trend as most sectors, including real estate, materials, and utilities, recorded losses.
This occurred as U.S. stocks settled mixed, with the S&amp;P 500 itself recording gains, as markets reacted to the U.S.-EU trade deal struck over the weekend.
The new agreement means the U.S. will impose a 15% tariff on EU imports like pharmaceuticals and automobiles, while certain sectors such as steel, aluminum, and copper will face steeper tariffs of up to 50%.
All three major indices closed the last week higher, with the 30-stock Dow gaining around 1.3% and the tech-heavy Nasdaq adding 1%. The broad market S&amp;P 500 climbed around 1.5% last week.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 3% after the U.S. announced lower-than-expected tariffs on European goods, including autos, and following CEO Elon Musk's revelation of a $16.5 billion deal with Samsung Electronics to produce next-generation chips.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.33%</td>
<td>21,178.58</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.018%</td>
<td>6,389.77</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.14%</td>
<td>44,837.56</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.19%</td>
<td>2,256.73</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Senior Economist Jeremy Siegel highlighted in his weekly commentary that the U.S. economy is still proving resilient despite global tensions and trade barriers.
However, he cautioned that investors should prepare for some economic drag as these tariffs take hold in the second half of the year. &#8220;The cumulative inflation impact from tariffs is likely to be modest, perhaps 1.5% to 2% over two years, while the GDP drag remains limited and manageable,&#8221; he said.
He explained that the market has come to terms with this dynamic and continues to look ahead to more powerful, longer-term forces, particularly the ongoing AI.
&#8220;I think the market rightly assesses this will buoy productivity and earnings. In particular, the immediate expensing provision for capital equipment that came in the ‘One Big Beautiful Bill' is a meaningful tailwind for corporate investment, counteracting some negative tariff effects.&#8221;
According to him, earnings season is not showing signs of a breakdown. While there is some cautious forward guidance, the tone has been far more constructive than feared. &#8220;I'm encouraged by year-end earnings estimates, which remain stable or even modestly positive. I continue to believe we are in a healthy bull market with no signs of internal deterioration,&#8221; he added.
From a valuation perspective, Siegel said that some argue markets are expensive.
&#8220;When measuring forward P/E ratios, we are increasingly pricing in next year's earnings, which are supported by strong productivity trends and expanding technology adoption. The 2025–2026 EPS outlook is solid, and while earnings might come down from lofty year-ahead outlooks, I continue to see upside in equities,&#8221; he added.
Meanwhile, Ryan Detrick from Carson Research also reiterated that the market rally has been &#8220;historic,&#8221; but it &#8220;likely has legs left.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Don&#39;t stop believing. This rally has been historic, but it likely has legs left. Talking with <a href="https://twitter.com/sonusvarghese?ref_src=twsrc%5Etfw">@sonusvarghese</a> about it all in our latest Facts vs Feelings &#x1f440; <a href="https://t.co/yzIlXWwqbZ">https://t.co/yzIlXWwqbZ</a> &#x1f3a7;<a href="https://t.co/rbZGmRxOa1">https://t.co/rbZGmRxOa1</a> <a href="https://t.co/5vPmnmJOOx">pic.twitter.com/5vPmnmJOOx</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1950002858570494054?ref_src=twsrc%5Etfw">July 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>June&#8217;s advanced U.S. trade balance in goods, retail inventories, and wholesale inventories data will be announced by 8:30 a.m. ET.</li>
<li>May&#8217;s S&amp;P Case-Shiller home price index for 20 cities will be out by 9:00 a.m., July&#8217;s consumer confidence data, and June&#8217;s job openings data will be released by 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) was up 0.14% in premarket on Tuesday as analysts expect it to report a quarterly loss of 94 cents per share on revenue of $20.20 billion before the opening bell.</li>
<li>Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) declined 0.41% as it is expected to report earnings before the opening bell. Analysts estimate earnings of $1.42 per share on revenue of $20.76 billion.</li>
<li>Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) was 0.18% higher as analysts expect it to report earnings of 65 cents per share on revenue of $9.29 billion after the closing bell.</li>
<li>Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) rose 0.48% after posting upbeat earnings for the second quarter, but lowered its FY2025 sales guidance.</li>
<li>Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) jumped 9.31% after posting better-than-expected earnings for the second quarter. Philips posted quarterly adjusted earnings of 41 cents per share, beating market estimates of 29 cents per share.</li>
<li>Cadence Design Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) climbed 6.52% after it lifted its full-year outlook after the second quarter results topped estimates.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 1.75% following the news of a new strategic partnership and reports of softened trade enforcement between the U.S. and China.</li>
<li>VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) tumbled 6.20% after declaring that its board has approved a stock repurchase plan of up to $1.11 billion in shares.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.79% to hover around $67.24 per barrel.
Gold Spot US Dollar rose 0.23% to hover around $3,322.20 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.17% at the 98.7980 level.
Asian markets mostly advanced on Tuesday, except Japan's Nikkei 225 and Hong Kong's Hang Seng indices. South Korea's Kospi, India's S&amp;P BSE Sensex, China&#8217;s CSI 300, and Australia's ASX 200 indices rose. European markets were mostly higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46679779/opendoor-skyrockets-314-in-a-month-amid-meme-stock-mania-hedge-fund-manager-who-reaped-windfall-gains-says-im-not-here-to-pump-up-a-stock">Opendoor Skyrockets 314% In A Month Amid Meme Stock Mania: Hedge Fund Manager Who Reaped Windfall Gains Says &#8216;I&#8217;m Not Here To Pump Up A Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

CDNS

SBUX

SMCI

VRSN

Stock Market Today: US Futures Rise Following S&P 500's 6-Days Of Record Close—Boeing, P&G, Starbucks Earnings In Focus

Stock of Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration&#8217;s (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta&#8217;s gene therapy for Duchenne Muscular Dystrophy.
What Happened: The FDA advised the removal of the voluntary hold on Elevidys, which had been implemented after the demise of an 8-year-old patient in Brazil. The FDA <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46676099/sarepta-therapeutics-stock-soars-after-fda-removes-hold-on-elevidys-for-some-patients">determined </a>that the death was unlikely to be related to treatment with Elevidys, the only approved gene therapy for Duchenne.
Sarepta&#8217;s CEO, Doug Ingram, expressed his contentment with the FDA&#8217;s prompt and comprehensive review, leading to the recommendation to recommence the distribution of Elevidys for ambulatory patients. However, the therapy for non-ambulatory patients continues to be on hold, as talks regarding the company&#8217;s risk-mitigation strategy are still underway with the FDA.
Following this development, Sarepta&#8217;s shares closed Monday with a 16.18% increase at $13.86.
SEE ALSO: <a href="https://benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46678150/cathie-wood-goes-on-a-20m-bitmine-immersion-bargain-hunt-as-ark-trims-robinhood-and-pa" target="_blank" rel="noreferrer noopener">Cathie Wood Goes On A $20M Bitmine Immersion Bargain Hunt As Ark Trims Robinhood And Palantir Stakes</a>
Why It Matters: This news comes as a significant development for Sarepta, especially considering the recent challenges the company has faced. The FDA had previously requested a <a href="https://www.benzinga.com/news/fda/25/07/46657622/fda-probes-death-of-8-year-old-who-received-sareptas-elevidys">voluntary suspension</a> of Elevidys distribution following the death of an 8-year-old boy who had received the therapy. This incident occurred on June 7, 2025, raising safety concerns about the therapy.
Furthermore, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46634492/sarepta-gets-thumbs-down-from-regulators-regarding-elevidys-gene-therapy">negative opinion</a> on the conditional marketing authorization (CMA) for Elevidys for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).
The FDA&#8217;s recommendation to lift the hold on Elevidys for certain patients is a positive step forward for Sarepta, potentially paving the way for the resumption of the therapy&#8217;s distribution and providing a boost to the company&#8217;s stock.
In another development, Arrowhead Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) has publicly stated that Sarepta owes it $100 million which it must repay within 60 days.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46599748/this-sarepta-therapeutics-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-thursday">This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ARWR

SRPT

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?

DVLT

Datavault AI Expands Commercialization Of DataScore And DataValue With IBM watsonx Integration Across Enterprise AI Workflows

Needham analyst Charles Shi maintains Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) with a Buy and raises the price target from $26 to $30.

UCTT

Needham Maintains Buy on Ultra Clean Hldgs, Raises Price Target to $30

Health Care

Press Releases

General

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Comments

Beyond Air

Beyond Air (XAIR) Opciones

Beyond Air (NASDAQ:XAIR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL